TY  - GEN
AU  - Shapiro,Geoffrey I
AU  - Rodon,Jordi
AU  - Bedell,Cynthia
AU  - Kwak,Eunice L
AU  - Baselga,Jose
AU  - Braña,Irene
AU  - Pandya,Shuchi S
AU  - Scheffold,Christian
AU  - Laird,A Douglas
AU  - Nguyen,Linh T
AU  - Xu,Yi
AU  - Egile,Coumaran
AU  - Edelman,Gerald
TI  - Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors
SN  - 1557-3265
PY  - 2014///0818
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Area Under Curve
KW  - Carcinoma, Non-Small-Cell Lung
KW  - drug therapy
KW  - Dose-Response Relationship, Drug
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Phosphatidylinositol 3-Kinase
KW  - metabolism
KW  - Phosphoinositide-3 Kinase Inhibitors
KW  - Quinoxalines
KW  - Signal Transduction
KW  - Skin Diseases
KW  - chemically induced
KW  - Sulfonamides
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1158/1078-0432.CCR-13-1777
ER  -